BRPI0518209A - agentes de ligação especìficos à angiopoietina-2 - Google Patents

agentes de ligação especìficos à angiopoietina-2

Info

Publication number
BRPI0518209A
BRPI0518209A BRPI0518209-3A BRPI0518209A BRPI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A
Authority
BR
Brazil
Prior art keywords
specific binding
binding agents
angiopoietin
antibodies
disclosed
Prior art date
Application number
BRPI0518209-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel Jonathon Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0518209A publication Critical patent/BRPI0518209A/pt

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0518209-3A 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2 BRPI0518209A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
BRPI0518209A true BRPI0518209A (pt) 2008-11-04

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518209-3A BRPI0518209A (pt) 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2

Country Status (10)

Country Link
JP (2) JP2008520188A (enrdf_load_stackoverflow)
CN (1) CN101495513B (enrdf_load_stackoverflow)
BR (1) BRPI0518209A (enrdf_load_stackoverflow)
EA (1) EA011866B1 (enrdf_load_stackoverflow)
IL (1) IL182279A0 (enrdf_load_stackoverflow)
MA (1) MA29015B1 (enrdf_load_stackoverflow)
MX (1) MX2007004247A (enrdf_load_stackoverflow)
RU (2) RU2404992C2 (enrdf_load_stackoverflow)
SG (1) SG156668A1 (enrdf_load_stackoverflow)
ZA (1) ZA200704020B (enrdf_load_stackoverflow)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
JP2014532053A (ja) * 2011-09-30 2014-12-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 治療用ペプチド
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
AU2015309862C1 (en) 2014-08-28 2020-10-15 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
EP3932946A4 (en) * 2019-02-25 2023-03-22 Pharmabcine Inc. ANTI-ANG2 ANTIBODIES AND ITS USE
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165115B1 (en) * 1999-03-26 2003-05-28 Regeneron Pharmaceuticals, Inc. Modulation of vascular permeability by mean of tie2 receptor activators
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EE200200706A (et) * 2000-06-23 2004-06-15 Schering Aktiengesellschaft VEGF-i/VEGF-retseptori ja angiopoetiini/Tie-retseptori funktsiooni mõjustavad kombinatsioonid ja kompositsioonid ning nende kasutamine (II)
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
ATE536868T1 (de) * 2001-10-12 2011-12-15 Monosolrx Llc Einheitliche filme als schnell auflösende verabreichungsformen enthaltend geschmacksmaskiereden stoff
EA011866B1 (ru) * 2004-10-19 2009-06-30 Амджен Инк. Агенты, специфически связывающие ангиопоэтин-2

Also Published As

Publication number Publication date
MA29015B1 (fr) 2007-11-01
IL182279A0 (en) 2007-07-24
EA200700876A1 (ru) 2007-10-26
SG156668A1 (en) 2009-11-26
JP2011207882A (ja) 2011-10-20
CN101495513A (zh) 2009-07-29
CN101495513B (zh) 2014-08-06
RU2404992C2 (ru) 2010-11-27
EA011866B1 (ru) 2009-06-30
ZA200704020B (en) 2008-06-25
RU2007118670A (ru) 2008-12-27
RU2010132956A (ru) 2012-02-10
JP2008520188A (ja) 2008-06-19
MX2007004247A (es) 2007-06-12

Similar Documents

Publication Publication Date Title
BRPI0518209A (pt) agentes de ligação especìficos à angiopoietina-2
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
RS28904A (en) Angiopoietin-2 specific binding agents
EA201070888A1 (ru) Антитела и их производные
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
CR10530A (es) Anticuerpos anti-dlla4 y metodos que los usan
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
ATE505489T1 (de) Tgf-beta-1-spezifische antikörper
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
GB2419993A (en) Improved search engine optimisation
CR20140081A (es) Agentes de fijación

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.